CHICAGO, Ill., May 29, 2026
Johnson & Johnson has announced encouraging long-term results from the Phase 1/1b CHRYSALIS-2 study, demonstrating that the combination of RYBREVANT® (amivantamab-vmjw) and LAZCLUZE® (lazertinib) delivered prolonged clinical benefit in patients with advanced non-small cell lung cancer (NSCLC) harboring atypical EGFR mutations. Presented during an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, the findings revealed a median overall survival approaching 3.5 years, significantly exceeding historical outcomes observed with currently available therapies. The data strengthen the growing evidence supporting RYBREVANT-based regimens as a potential treatment strategy across multiple EGFR mutation subtypes and highlight Johnson & Johnson’s commitment to advancing precision oncology for difficult-to-treat lung cancers.
CHRYSALIS-2 Trial Demonstrates Durable Long-Term Survival
The updated analysis from Cohort C of the CHRYSALIS-2 trial evaluated RYBREVANT plus LAZCLUZE as a first-line treatment in patients with atypical EGFR-mutated advanced NSCLC, excluding exon 20 insertion and classical EGFR mutations. Among the 49 patients enrolled, the study demonstrated a median overall survival of 41 months, representing nearly 3.5 years of survival benefit in a patient population historically associated with poor outcomes. Researchers also reported that 55% of patients remained alive at three years, while 46% survived beyond four years, underscoring the durability of treatment benefit.
Earlier analyses had already shown an impressive 57% objective response rate, and the newly reported survival findings further validate the combination’s ability to provide sustained disease control. Importantly, responses were observed consistently across multiple atypical EGFR mutation subgroups, including patients carrying mutations traditionally linked to lower treatment success rates and more aggressive disease progression.
Addressing a Significant Unmet Need in Atypical EGFR Lung Cancer
Advertisement
Atypical EGFR mutations account for approximately 10% to 20% of all EGFR-mutated NSCLC cases, yet treatment options remain limited compared with therapies available for common EGFR mutations. Patients with these rare molecular alterations often experience inferior clinical outcomes and shorter survival durations when treated with standard EGFR tyrosine kinase inhibitors. Johnson & Johnson noted that median overall survival with existing single-agent therapies typically remains below two years in this setting.
RYBREVANT’s unique mechanism of action may help address this challenge by simultaneously targeting both EGFR and MET pathways, while also activating immune-mediated anti-tumor responses. These complementary mechanisms are designed to overcome tumor growth drivers and resistance pathways that frequently limit the effectiveness of conventional targeted therapies. The latest findings suggest that a multi-targeted treatment approach could redefine expectations for patients with atypical EGFR-mutated disease and potentially establish a new benchmark for first-line therapy.
Consistent Efficacy Supports Expanding Precision Oncology Strategy
Beyond overall survival improvements, the CHRYSALIS-2 study demonstrated durable treatment exposure across patient groups, with 41% of participants remaining on RYBREVANT therapy for two years or longer. Clinical activity was observed regardless of baseline characteristics, including patients with central nervous system metastases and those with TP53 mutations. The safety profile remained consistent with previous studies, with no new safety concerns identified during extended follow-up.
Most adverse events were manageable and classified as Grade 1 or Grade 2 in severity. The ASCO 2026 presentation further reinforces the growing clinical value of RYBREVANT-based regimens, which are already approved for multiple EGFR-mutated NSCLC indications. Johnson & Johnson is also evaluating the therapy across additional solid tumors, including head and neck cancers and colorectal cancer. As precision medicine continues to reshape oncology treatment paradigms, the company’s latest survival data highlight the potential of targeted combination therapies to deliver more durable outcomes for patients with genetically defined cancers that have historically lacked effective treatment options.
Source: Johnson & Johnson press release
